# Beijing Gene Key Life Technology Co., Ltd: Phase 1 study in Hepatocellular Carcinoma (HCC), Unresectable Hepatocellular Carcinoma (13 participants)

**Score:** 40/100

| Field | Value |
|---|---|
| Sponsor | Beijing Gene Key Life Technology Co., Ltd |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GKL-006 Injection in Combination With TACE in Unresectable Hepatocellular Carcinoma |
| NCT ID | NCT07845266 |
| Phase | Phase 1 |
| Status | completed |
| Conditions | Hepatocellular Carcinoma (HCC); Unresectable Hepatocellular Carcinoma |
| Intervention types | biological, drug |
| Target enrollment | 13 |
| Site countries | China |
| Posted | 2026-09-28 |
| Planned start | 2024-04-16 |
| Event | Newly registered study |
| Event date | 2026-09-28 |

## Why this score
- Industry sponsor (buys outsourced services).

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07845266). Last refreshed: 2026-11-05T08:46:16.625Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.